Response to Alemtuzumab for Leukemic Cutaneous T-Cell LymphomaResponse to Alemtuzumab for Leukemic Cutaneous T-Cell Lymphoma

Patients with leukemic cutaneous T-cell lymphoma (CTCL) who have diffuse erythema are more likely to experience complete response to alemtuzumab therapy, according to results from a small series. Reuters Health Information
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Hematology-Oncology News Source Type: news